Skip Navigation


Rheumatology Advance Access originally published online on March 16, 2004
Rheumatology 2004 43(8):960-964; doi:10.1093/rheumatology/keh178
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/8/960    most recent
keh178v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schotte, H.
Right arrow Articles by Gaubitz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schotte, H.
Right arrow Articles by Gaubitz, M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 8 © British Society for Rheumatology 2004; all rights reserved

Paper

Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis

H. Schotte, B. Schlüter1, P. Willeke, E. Mickholz, M. A. Schorat, W. Domschke and M. Gaubitz

Medizinische Klinik und Poliklinik B and 1 Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Münster, Germany.

Correspondence to: H. Schotte, Department of Medicine B, Münster University Hospital, Albert-Schweitzer-Str. 33, D-48129 Münster, Germany. E-mail: h.schotte{at}uni-muenster.de

Objectives. To determine the influence of etanercept treatment on the number of peripheral blood mononuclear cells (PBMC) secreting immunoregulatory key cytokines and the correlation of these cell counts with treatment response in patients with rheumatoid arthritis (RA).

Methods. Nineteen patients with RA were treated with etanercept as monotherapy. Frequencies of PBMC secreting cytokines were determined by ELISPOT analysis before and after 9 months of therapy and compared with values for healthy controls (HC). The clinical outcome was assessed as defined by the ACR criteria.

Results. Fifteen patients fulfilled the ACR20, seven patients the ACR50 and two patients the ACR70 criteria. Initially elevated numbers of tumour necrosis factor-{alpha}- and interleukin (IL)-1ß-secreting PBMC were reduced to HC levels, and normal or low numbers of IL-6- and interferon-{gamma} (IFN-{gamma})-secreting PBMC were reduced below HC levels. The number of IL-10-secreting PBMC did not differ from that in HC and did not change significantly over time. The pretreatment IFN-{gamma}:IL-10 ratio correlated to reduction in the tender and swollen joint counts.

Conclusions. Long-term treatment with etanercept in patients with RA significantly reduces the numbers of proinflammatory cytokine-secreting PBMC, while the number of IL-10-secreting cells is unaffected. Although the changes described did not affect the safety or efficacy of etanercept therapy, these alterations may account for the long-term systemic effects. The pretreatment IFN-{gamma}:IL-10 ratio may be of prognostic value in predicting the improvement in joint symptoms.

KEY WORDS: Rheumatoid arthritis, Etanercept, Peripheral blood mononuclear cells, ELISPOT, Tumour necrosis factor-{alpha}, Interleukin-1, Interleukin-6, Interleukin-10, Interferon-{gamma}


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Ehling, A. Schaffler, H. Herfarth, I. H. Tarner, S. Anders, O. Distler, G. Paul, J. Distler, S. Gay, J. Scholmerich, et al.
The Potential of Adiponectin in Driving Arthritis
J. Immunol., April 1, 2006; 176(7): 4468 - 4478.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M. V. Abello, M. A. Lowes, F. Chen, M. Magliocco, and J. G. Krueger
TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
J. Immunol., August 15, 2005; 175(4): 2721 - 2729.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.